Most remarkably, more than 90% of IDH-mutant gliomas exhibit hypermethylation of the MGMT promoter [4,49], indicating that these profound epigenetic alterations are strongly associated with IDH mutations [50]. The gene discussed is IDH2; the disease is central nervous system cancer.